[Opinion] Should the 90% CI for GMR be required to encompass 1 [RSABE / ABEL]

posted by jag009  – NJ, 2018-03-29 21:55 (2586 d 13:10 ago) – Posting: # 18619
Views: 11,420

Hi,

❝ Actually, I am questioning the validity of FDA's Swr scaled 10% window on BE for NTID.


❝ If a GMR of 1.1 is clinically relevant (i.e. a test should be sensitive for this), and the NTID with a Swr of .22 will pass by ABE, this is a failure IMO.


Before we go further, does your hypothetical example pass the other two criteria stated in the NTI guidance?

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
81 visitors (0 registered, 81 guests [including 2 identified bots]).
Forum time: 11:06 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5